Report cover image

Daxor Corp (DXR) - Financial and Strategic SWOT Analysis Review

Publisher GlobalData
Published Apr 20, 2026
Length 50 Pages
SKU # GBDT21121758

Description

Daxor Corp (DXR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Daxor Corp (Daxor) is a biotechnology company, which offers original medical equipment for medical personnel. The company manufactures blood volume analyzers. Its flagship product, BVA-100 blood volume analyzer is an instrument to measure human blood volume. The product is used in conjunction with Volumex, a diagnostic radiopharmaceutical containing iodinated I 131 albumins. It finds application in a range of medical and surgical conditions which includes congestive heart failure, intensive care unit medicine, critical care medicine, syncope, kidney failure, hypertension, renal failure, red blood cell abnormalities, hyponatremia and other conditions. The company offers its product to hospitals, clinics, and physicians. Daxor is headquartered in Oak Ridge, Tennessee, the US.

Daxor Corp Key Recent Developments

Apr 08,2026: Daxor Launches BVA Program at High-Volume Ohio Cardiology Center
Mar 10,2026: Daxor to Debut Rapid Portable Blood Volume Analyzer at SCCM 2026 Critical Care Congress
Mar 03,2026: Daxor Corporation Reports 2025 Fiscal Year Results; Operating Revenue Up 45% and Net Asset Value Rises to $9.07 Per Share
Mar 03,2026: Daxor CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Table of Contents

50 Pages
Section 1 - About the Company
Daxor Corp - Key Facts
Daxor Corp - Key Employees
Daxor Corp - Key Employee Biographies
Daxor Corp - Major Products and Services
Daxor Corp - History
Daxor Corp - Company Statement
Daxor Corp - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Daxor Corp - Business Description
R&D Overview
Daxor Corp - Corporate Strategy
Daxor Corp - SWOT Analysis
SWOT Analysis - Overview
Daxor Corp - Strengths
Daxor Corp - Weaknesses
Daxor Corp - Opportunities
Daxor Corp - Threats
Daxor Corp - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Daxor Corp, Medical Equipment, Deals By Year, 2020 to YTD 2026
Daxor Corp, Medical Equipment, Deals By Type, 2020 to YTD 2026
Daxor Corp, Recent Deals Summary
Section 5 – Company’s Recent Developments
Apr 08, 2026: Daxor Launches BVA Program at High-Volume Ohio Cardiology Center
Mar 10, 2026: Daxor to Debut Rapid Portable Blood Volume Analyzer at SCCM 2026 Critical Care Congress
Mar 03, 2026: Daxor Corporation Reports 2025 Fiscal Year Results; Operating Revenue Up 45% and Net Asset Value Rises to $9.07 Per Share
Mar 03, 2026: Daxor CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders
Feb 24, 2026: Daxor Expands Outpatient Presence With BVA Diagnostic Program in Tennessee
Feb 10, 2026: Daxor Corporation To Transition To Securities Exchange Act Reporting, Reaffirms Focus On Blood Volume Diagnostic Business
Nov 25, 2025: Daxor Expands BVA Platform to Three Facilities and Deploys New Analyzer
Nov 25, 2025: Daxor Fuels Growth With Three New Facility Adoptions and Deployment of Next-Generation BVA Analyzer
Sep 23, 2025: Daxor Corporation Introduces Next-Gen BVA Analyzer at HFSA Annual Scientific Meeting
Jul 22, 2025: Daxor’s Blood Volume Analysis Technology Accelerates Market Penetration With Three New Facility Adoptions
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
List of Tables
Daxor Corp, Key Facts
Daxor Corp, Key Employees
Daxor Corp, Key Employee Biographies
Daxor Corp, Major Products and Services
Daxor Corp, History
Daxor Corp, Subsidiaries
Daxor Corp, Key Competitors
Daxor Corp, Ratios based on current share price
Daxor Corp, Annual Ratios
Daxor Corp, Annual Ratios (Cont...1)
Daxor Corp, Interim Ratios
Daxor Corp, Medical Equipment, Deals By Year, 2020 to YTD 2026
Daxor Corp, Medical Equipment, Deals By Type, 2020 to YTD 2026
Daxor Corp, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
List of Figures
Daxor Corp, Performance Chart (2021 - 2025)
Daxor Corp, Ratio Charts
Daxor Corp, Medical Equipment, Deals By Year, 2020 to YTD 2026
Daxor Corp, Medical Equipment, Deals by Type, 2020 to YTD 2026

Search Inside Report

How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.